Firefly Neuroscience shares rise 23.21% intraday after announcing a public-private partnership with the U.S. Department of War to deploy its FDA 510k-licensed AI EEG/ERP platform for treating PTSD and TBI in military personnel.

Firefly Neuroscience surged 23.21% in intraday trading, following an announcement that it has entered a public-private partnership with the U.S. Department of Defense to deploy its FDA 510k-licensed, AI-driven EEG/ERP technology platform for assessing and treating PTSD and TBI in military personnel, marking the company's expansion into the U.S. government and defense health sectors.